<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "15: license fee from", fill: "#880085"},
{source: "15: license fee from", target: "15: Ortho Biotech ", fill: "#880085"},
{source: "15: Ortho Biotech ", target: "15: joint collaboration", fill: "#880085"},
{source: "15: joint collaboration", target: "15: commercialization", fill: "#880085"},
{source: "15: license fee from", target: "17: December ", fill: "#ffa343"},
{source: "17: December ", target: "17: net revenues from", fill: "#ffa343"},
{source: "17: net revenues from", target: "17: development expenses", fill: "#ffa343"},
{source: "17: development expenses", target: "17: connection with", fill: "#ffa343"},
{source: "17: connection with", target: "17: clinical trials", fill: "#ffa343"},
{source: "17: December ", target: "18: regulatory approval", fill: "#7b1113"},
{source: "18: regulatory approval", target: "18: product candidates", fill: "#7b1113"},
{source: "18: product candidates", target: "18: additional", fill: "#7b1113"},
{source: "18: additional", target: "18: marketing expenses", fill: "#7b1113"},
{source: "18: marketing expenses", target: "18: increased manufacturing", fill: "#7b1113"},
{source: "18: regulatory approval", target: "19: additional funding", fill: "#ce2029"},
{source: "19: additional funding", target: "19: which would force us", fill: "#ce2029"},
{source: "19: which would force us", target: "19: delay reduce", fill: "#ce2029"},
{source: "19: delay reduce", target: "19: product development programs", fill: "#ce2029"},
{source: "19: product development programs", target: "19: commercialization efforts", fill: "#ce2029"},
{source: "19: additional funding", target: "20: raise additional capital", fill: "#ed9121"},
{source: "20: raise additional capital", target: "20: operations", fill: "#ed9121"},
{source: "20: operations", target: "20: clinical trials", fill: "#ed9121"},
{source: "20: clinical trials", target: "20: development", fill: "#ed9121"},
{source: "20: development", target: "20: commercialize", fill: "#ed9121"},
{source: "20: commercialize", target: "20: product candidates", fill: "#ed9121"},
{source: "20: product candidates", target: "20: such product candidates", fill: "#ed9121"},
{source: "20: such product candidates", target: "20: regulatory approval", fill: "#ed9121"},
{source: "20: regulatory approval", target: "20: commercial sale", fill: "#ed9121"},
{source: "20: raise additional capital", target: "40: purchase from", fill: "#138808"},
{source: "40: purchase from", target: "40: worldwide requirements", fill: "#138808"},
{source: "40: worldwide requirements", target: "40: active pharmaceutical", fill: "#138808"},
{source: "40: active pharmaceutical", target: "40: ACAPODENE ", fill: "#138808"},
{source: "40: ACAPODENE ", target: "40: agreement", fill: "#138808"},
{source: "40: purchase from", target: "42: could delay", fill: "#b7410e"},
{source: "42: could delay", target: "42: development", fill: "#b7410e"},
{source: "42: development", target: "42: commercialize", fill: "#b7410e"},
{source: "42: commercialize", target: "42: ACAPODENE ", fill: "#b7410e"},
{source: "42: ACAPODENE ", target: "42: may terminate", fill: "#b7410e"},
{source: "42: may terminate", target: "42: obligation", fill: "#b7410e"},
{source: "42: obligation", target: "42: supply us with toremifene", fill: "#b7410e"},
{source: "42: supply us with toremifene", target: "42: manufacture", fill: "#b7410e"},
{source: "42: manufacture", target: "42: toremifene permanently", fill: "#b7410e"},
{source: "42: toremifene permanently", target: "42: commercial sale", fill: "#b7410e"},
{source: "42: commercial sale", target: "42: United States ", fill: "#b7410e"},
{source: "42: United States ", target: "42: December ", fill: "#b7410e"},
{source: "42: could delay", target: "START_HERE", fill: "#b7410e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Insurance</td>
    </tr>
    <tr>
      <td>Property and Casualty Insurance</td>
    </tr>
    <tr>
      <td>Life and Health Insurance</td>
    </tr>
    <tr>
      <td>Insurance Brokers</td>
    </tr>
    <tr>
      <td>Multi-line Insurance</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Toremifene">Toremifene</a></td>
      <td>Toremifene, sold under the brand name Fareston among others, is a medication which is used in the treatment of advanced breast cancer in postmenopausal women. It is taken by mouth.Side effects of toremifene include hot flashes, sweating, nausea, vomiting, dizziness, vaginal discharge, and vaginal bleeding.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GTX INC /DE/      ITEM 1A   RISK FACTORS          We have identified the <font color="blue">following <font color="blue">additional</font> risks</font> and <font color="blue">uncertainties</font>     that may have a material adverse effect on our business, <font color="blue">financial condition</font>     or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font><font color="blue">should carefully</font> consider the risks     described below before making an <font color="blue"><font color="blue">investment</font> decision</font></td>
    </tr>
    <tr>
      <td>Our business faces     <font color="blue"><font color="blue">significant</font> risks</font> and the <font color="blue">risks described</font> below may not be the only risks we     face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font> to us or that we currently     believe  are  immaterial  may  also  <font color="blue"><font color="blue">significant</font>ly impair</font> our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of these risks occur, our business, results of <font color="blue">operations</font>     or <font color="blue">financial condition</font> could suffer, the <font color="blue">market price</font> of our <font color="blue">common stock</font>     <font color="blue">could decline</font> and you <font color="blue">could lose</font> all or part of your <font color="blue">investment</font> in our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Financial Results and Need for <font color="blue">Additional </font>Financing       We have <font color="blue">incurred losses since inception</font> and anticipate that we will incur     <font color="blue">continued losses</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an     <font color="blue">accumulated deficit</font> of dlra194dtta3 million, of which dlra96dtta3 million related to     non-cash dividends and <font color="blue">adjustments</font> to the <font color="blue"><font color="blue">preferred stock</font> redemption value</font></td>
    </tr>
    <tr>
      <td>We have incurred losses in <font color="blue">each year since</font> our inception in 1997</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur <font color="blue">significant</font></font> and increasing operating     losses for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>These losses have had and <font color="blue">will continue</font>     to have an adverse effect on our <font color="blue">stockholders</font>’ equity and working capital</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of  the numerous risks and <font color="blue">uncertainties</font> associated with     developing small molecule drugs, we are unable to predict the extent of any     <font color="blue">future losses</font> or when we <font color="blue">will <font color="blue">become profitable</font></font>, if at all</td>
    </tr>
    <tr>
      <td>We have financed     our <font color="blue">operations</font> and <font color="blue">internal growth almost exclusively through sales</font> of     common  stock and <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>In addition, we received an upfront     <font color="blue">license fee from</font> <font color="blue">Ortho Biotech </font>in March 2004 for our <font color="blue">joint <font color="blue">collaboration</font></font> for     the <font color="blue">development</font> and <font color="blue">commercialization</font> of andarine and other licensed SARM     compounds that <font color="blue">Ortho Biotech </font>may choose to develop</td>
    </tr>
    <tr>
      <td>FARESTON is currently     our <font color="blue">only commercial product</font> and, we expect, <font color="blue">will account</font> for all of our     <font color="blue">product revenue</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>For the twelve months ended     <font color="blue">December </font>31, 2005, we recognized dlra2dtta4 million in <font color="blue">net revenues from</font> the sale     of <font color="blue">FARESTON     </font>     We  expect  our  research and <font color="blue"><font color="blue">development</font> expenses</font> to increase in     <font color="blue">connection with</font> our conduct of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, subject to     <font color="blue"><font color="blue">regulatory</font> approval</font> of any of our <font color="blue">product <font color="blue">candidates</font></font>, we expect to incur     <font color="blue">additional</font>  sales  and  <font color="blue">marketing expenses</font> and <font color="blue">increased <font color="blue">manufacturing</font></font>     expenses</td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue">additional</font> funding and may be unable to raise     capital when needed, <font color="blue">which would force us</font> to delay, reduce or eliminate our     <font color="blue">product <font color="blue">development</font> programs</font> or <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>We will need to raise <font color="blue">additional</font> capital to:       •   fund our <font color="blue">operations</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   continue our research and <font color="blue">development</font>; and         •   <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, if any such <font color="blue">product <font color="blue">candidates</font></font>     receive <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We estimate that our current cash resources, interest on these funds     and <font color="blue">product revenue</font> from the sale of FARESTON will be sufficient to meet our     projected  operating <font color="blue"><font color="blue">requirements</font> through</font> the first half of 2007</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>estimate includes a <font color="blue">milestone payment</font> we will receive from <font color="blue">Ortho Biotech </font>    <font color="blue">upon initiation</font> of our <font color="blue">Phase II </font><font color="blue">clinical trial</font> for andarine but does not     include <font color="blue">funding from</font> other <font color="blue">milestone payment</font>s that we may receive under our     existing <font color="blue">collaboration</font>, potential future <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> with     <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, or the <font color="blue">potential future issuance</font> and sale of our     securities</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [85]Table of <font color="blue"><font color="blue">Contents       </font>     </font>Our future funding <font color="blue">requirements</font> will depend on many factors, including:       •   the scope, rate of progress and cost of our <font color="blue"><font color="blue">clinical trial</font>s</font> and other     research and <font color="blue">development</font> <font color="blue">activities</font>;         •   future <font color="blue">clinical trial</font> results;          •    the terms and timing of any <font color="blue">collaborative</font>, licensing and other     <font color="blue"><font color="blue">arrangement</font>s</font> that we <font color="blue">may establish</font>;          •     the  <font color="blue">achievement</font>  of <font color="blue">certain milestone events under</font> our joint     <font color="blue">collaboration</font> and <font color="blue">license <font color="blue">agreement</font> with</font> Ortho Biotech;         •   the cost and timing of <font color="blue"><font color="blue">regulatory</font> approval</font>s;          •   potential future licensing fees, <font color="blue">milestone payment</font>s and royalty     payments;         •   the cost and timing of <font color="blue">establishing</font> sales, marketing and <font color="blue">distribution</font>     <font color="blue">capabilities</font>;         •   the cost of <font color="blue">establishing</font> clinical and commercial supplies of our     <font color="blue">product <font color="blue">candidates</font></font> and any products that we may develop;         •   the effect of <font color="blue">competing technological</font> and market <font color="blue">development</font>s;         •   the cost of filing, prosecuting, defending and enforcing any patent     claims and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>; and         •   the extent to which we acquire or invest in businesses, products and     <font color="blue">technologies</font>,  although we currently have <font color="blue">no commitments</font> or <font color="blue"><font color="blue">agreement</font>s</font>     relating to any of these types of <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>Until we can generate a <font color="blue">sufficient amount</font> of <font color="blue">product revenue</font>, we expect     to <font color="blue">finance future cash</font> needs <font color="blue">through public</font> or <font color="blue">private equity offerings</font>,     <font color="blue"><font color="blue">debt financing</font>s</font> or <font color="blue">collaboration</font> and licensing <font color="blue"><font color="blue">arrangement</font>s</font>, such as our     <font color="blue">collaboration</font> with Ortho Biotech, <font color="blue">as well as through interest income earned</font>     <font color="blue">on cash balances</font></td>
    </tr>
    <tr>
      <td>If  we  raise  <font color="blue">additional</font> funds by issuing equity securities, our     <font color="blue"><font color="blue">stockholders</font> will</font> experience dilution</td>
    </tr>
    <tr>
      <td>Debt financing, if available, may     <font color="blue">involve restrictive covenants</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">debt financing</font> or <font color="blue">additional</font> equity that     we <font color="blue">raise may contain terms</font> that are not favorable to us or our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds through <font color="blue">collaboration</font> or licensing <font color="blue"><font color="blue">arrangement</font>s</font>     <font color="blue">with <font color="blue">third parties</font></font>, it will be <font color="blue">necessary</font> to <font color="blue">relinquish</font> some rights to our     <font color="blue">technologies</font> or our <font color="blue">product <font color="blue">candidates</font></font>, or we may be required to grant     <font color="blue">licenses on terms</font> that may not be favorable to us</td>
    </tr>
    <tr>
      <td>Risks Related to Development of Product Candidates       We  will  not  be  able to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> if our     <font color="blue">preclinical studies</font> do not produce successful results or our <font color="blue"><font color="blue">clinical trial</font>s</font>     do not <font color="blue">demonstrate safety</font> and efficacy in humans</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>and <font color="blue">clinical testing</font> is expensive, can take many years and     has an uncertain outcome</td>
    </tr>
    <tr>
      <td>Success in pre<font color="blue">clinical testing</font> and early clinical     trials does not ensure that later <font color="blue"><font color="blue">clinical trial</font>s</font> will be successful, and     interim  results  of a <font color="blue">clinical trial</font> do not <font color="blue">necessarily predict final</font>     results</td>
    </tr>
    <tr>
      <td>Typically, the failure rate for <font color="blue">development</font> <font color="blue">candidates</font> is high</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in <font color="blue"><font color="blue">clinical testing</font> could materially impact</font> our product     <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>We do not know whether planned <font color="blue"><font color="blue">clinical trial</font>s</font> will begin     on time, will need to be <font color="blue">restructured</font> or will be completed on schedule, if     at all</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">numerous unforeseen events during</font>, or as a result     of, pre<font color="blue">clinical testing</font> and the <font color="blue">clinical trial</font> process that <font color="blue">could delay</font> or     prevent our ability to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, including:       •   <font color="blue">regulators</font> or <font color="blue">institutional review boards may</font> not <font color="blue">authorize us</font> to     commence a <font color="blue">clinical trial</font> or conduct a <font color="blue">clinical trial</font> at a <font color="blue">prospective trial</font>     site;          •     our  preclinical  or  <font color="blue"><font color="blue">clinical trial</font>s</font> may produce negative or     <font color="blue">inconclusive</font> results, which may require us to conduct <font color="blue">additional</font> preclinical     or <font color="blue">clinical testing</font> or to abandon projects that we expect to be promising;         •   <font color="blue">registration</font> or <font color="blue">enrollment</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">slower than</font>     we currently anticipate, resulting in <font color="blue"><font color="blue">significant</font> delays</font>;         •   we might have to suspend or terminate our <font color="blue"><font color="blue">clinical trial</font>s</font> if the     <font color="blue">participating patients</font> are being exposed to unacceptable <font color="blue">health risks</font>;                                         29       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font>  •   <font color="blue">regulators</font> or <font color="blue">institutional review boards may</font> suspend or terminate     <font color="blue">clinical research</font> for <font color="blue">various reasons</font>, including <font color="blue">noncompliance with</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font>; and         •   our <font color="blue">product <font color="blue">candidates</font></font> may not have the desired effects or may include     undesirable side effects</td>
    </tr>
    <tr>
      <td>If  any  of  these events were to occur and, as a result, we have     <font color="blue"><font color="blue">significant</font> delays</font> in or <font color="blue">termination</font> of <font color="blue"><font color="blue">clinical trial</font>s</font>, our <font color="blue">costs could</font>     increase and our ability to <font color="blue"><font color="blue">generate revenue</font> could</font> be impaired, which would     <font color="blue"><font color="blue">adversely</font> impact</font> our financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related to Our <font color="blue">Dependence </font></font>on Third Parties       If <font color="blue">third parties</font> do not <font color="blue">manufacture</font> our <font color="blue">product <font color="blue">candidates</font></font> in sufficient     quantities  and  at  an  acceptable  cost,  clinical  <font color="blue">development</font>  and     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> would be delayed</td>
    </tr>
    <tr>
      <td>We do not currently own or operate <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font>, and we     rely, and expect to continue to rely, on <font color="blue">third parties</font> for the production of     clinical and <font color="blue">commercial quantities</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our current     and anticipated <font color="blue">future dependence upon others</font> for the <font color="blue">manufacture</font> of our     <font color="blue">product <font color="blue">candidates</font></font> may <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">future profit margins</font> and our     ability  to  develop  <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">commercialize</font> any product     <font color="blue">candidates</font> on a timely and <font color="blue"><font color="blue">competitive</font> basis</font></td>
    </tr>
    <tr>
      <td>We have agreed to <font color="blue">purchase from</font> Orion our <font color="blue">worldwide <font color="blue">requirements</font></font> of     toremifene, the <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient in ACAPODENE, in finished     tablet  form  at  specified transfer prices under a license and supply     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We rely on Orion as a <font color="blue">single source supplier</font> for <font color="blue">ACAPODENE </font>In     the event that Orion terminates the <font color="blue">agreement</font> due to our uncured material     breach or <font color="blue">bankruptcy</font>, we would not be able to <font color="blue">manufacture</font> <font color="blue">ACAPODENE </font>until     Orion’s <font color="blue"><font color="blue">patents with</font> respect</font> to the <font color="blue">composition</font> of matter of toremifene, the     <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient in ACAPODENE, expire</td>
    </tr>
    <tr>
      <td>This <font color="blue">could delay</font> the     <font color="blue">development</font>  of  and impair our ability to <font color="blue">commercialize</font> <font color="blue">ACAPODENE </font>In     addition, Orion <font color="blue">may terminate</font> its <font color="blue">obligation</font> to <font color="blue">supply us with toremifene</font> if     Orion ceases its <font color="blue">manufacture</font> of <font color="blue">toremifene <font color="blue">permanently</font></font>, or if <font color="blue">ACAPODENE </font>is     not approved for <font color="blue">commercial sale</font> in the <font color="blue"><font color="blue">United States</font> </font>by <font color="blue">December </font>31, 2009</td>
    </tr>
    <tr>
      <td>If  such  <font color="blue">termination</font>  occurs because Orion is <font color="blue">no longer <font color="blue">manufacturing</font></font>     toremifene, or because such <font color="blue"><font color="blue">regulatory</font> approval</font> is not obtained prior to the     <font color="blue">specified date</font>, we will have the right to <font color="blue">manufacture</font> ACAPODENE, but we     would be required to make <font color="blue"><font color="blue">arrangement</font>s</font> with a <font color="blue">qualified alternative supplier</font>     and obtain FDA approval of <font color="blue">such supplier</font> to do so</td>
    </tr>
    <tr>
      <td>We  also  rely  on  Orion  to <font color="blue">cooperate with us</font> in the filing and     maintenance  of  <font color="blue">regulatory</font> filings with respect to the <font color="blue">manufacture</font> of     <font color="blue">ACAPODENE </font>Orion <font color="blue">may terminate</font> its <font color="blue">obligation</font> to <font color="blue">assist us</font> in obtaining and     maintaining <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">ACAPODENE </font>if we do not receive <font color="blue">regulatory</font>     approval  for  <font color="blue">ACAPODENE </font>by <font color="blue">December </font>31, 2009</td>
    </tr>
    <tr>
      <td>If Orion terminates its     <font color="blue">obligation</font> to cooperate in these <font color="blue">activities</font>, or does not <font color="blue">cooperate with us</font>     or  otherwise  does not <font color="blue"><font color="blue">successfully</font> file</font> or maintain these <font color="blue">regulatory</font>     filings,  we  would  be required to make <font color="blue"><font color="blue">arrangement</font>s</font> with a qualified     alternative supplier, which <font color="blue">could delay</font> or prevent <font color="blue"><font color="blue">regulatory</font> approval</font> of     <font color="blue">ACAPODENE </font>         Under our <font color="blue">joint <font color="blue">collaboration</font></font> and <font color="blue">license <font color="blue">agreement</font> with</font> Ortho Biotech,     <font color="blue">Ortho Biotech </font>is responsible for the <font color="blue">manufacture</font>, packaging and supply of     andarine for both <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We relied on Eagle     Picher Pharmaceutical Services as our <font color="blue">single supplier</font> for ostarine, but     currently have <font color="blue">sufficient supply</font> to complete our planned <font color="blue">Phase II </font>clinical     trials</td>
    </tr>
    <tr>
      <td>Eagle Picher Technologies, LLC, the parent company of Eagle Picher     Pharmaceutical Services, had <font color="blue">previously filed</font> for <font color="blue">protection under</font> the     <font color="blue">bankruptcy</font> code, but has <font color="blue">secured new financing</font> and expects to <font color="blue">emerge from</font>     <font color="blue">bankruptcy</font> in 2006</td>
    </tr>
    <tr>
      <td>We are <font color="blue">evaluating whether</font> to transfer the <font color="blue">manufacturing</font>     process to another contract <font color="blue">manufacture</font>r and expect to make a decision the     first half of the year</td>
    </tr>
    <tr>
      <td>If our <font color="blue">current supply</font> of ostarine becomes unusable,     if our <font color="blue">ostarine supply</font> is not sufficient to complete our planned <font color="blue">Phase II </font>    clinical  trials,  or if we are <font color="blue">unsuccessful</font> in identifying a contract     <font color="blue">manufacture</font>r or <font color="blue">negotiating</font> a <font color="blue">manufacturing</font> <font color="blue">agreement</font> on a <font color="blue">timely basis</font>, we     could experience a delay in receiving an <font color="blue">adequate supply</font> of ostarine for use     in our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we     are  unable  to  continue  <font color="blue">relationships</font>  with Orion for <font color="blue">ACAPODENE </font>and     EaglePicher or <font color="blue">Ortho Biotech </font>for andarine, or to do so at an acceptable     cost, or if these or other <font color="blue">suppliers fail</font> to meet our <font color="blue">requirements</font> for these     <font color="blue">product <font color="blue">candidates</font></font> or for ostarine for any reason, we would be required to     obtain <font color="blue">alternate suppliers</font></td>
    </tr>
    <tr>
      <td>However, we may not be permitted to obtain     <font color="blue">alternate suppliers</font> for <font color="blue">ACAPODENE </font>under our <font color="blue">license <font color="blue">agreement</font> with</font> Orion if     Orion terminates its supply of <font color="blue">ACAPODENE </font>due to our uncured material breach     or <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to obtain <font color="blue">alternate suppliers</font>, including an     <font color="blue">inability</font> to obtain approval of an <font color="blue">alternate supplier from</font> the FDA, would     delay or prevent the clinical <font color="blue">development</font> and <font color="blue">commercialization</font> of these     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Use of third-party <font color="blue">manufacture</font>rs may increase the risk that we will not have     <font color="blue">adequate supplies</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Reliance on third-party <font color="blue">manufacture</font>rs entails risks to which we would     not be subject if we <font color="blue">manufacture</font>d <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">products ourselves</font>,     including:       •   <font color="blue">reliance on</font> the <font color="blue">third party</font> for <font color="blue">regulatory</font> compliance and quality     assurance;         •   the <font color="blue">possible breach</font> of the <font color="blue">manufacturing</font> <font color="blue">agreement</font> by the <font color="blue">third party</font>     because of <font color="blue">factors beyond</font> our control;         •   the possible <font color="blue">termination</font> or non-renewal of the <font color="blue">agreement</font> by the third     party, based on its own business priorities, at a time that is costly or     <font color="blue">inconvenient</font> for us;          •     the  <font color="blue">possible exercise by</font> Orion of its right to terminate its     <font color="blue">obligation</font> to <font color="blue">supply us with toremifene</font>;         o   if it <font color="blue">permanently</font> ceases <font color="blue">manufacture</font> of toremifene or if we do not     obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">ACAPODENE </font>prior to <font color="blue">December </font>31, 2009; and         o   if Orion <font color="blue">terminates due</font> to our uncured material breach or <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>If  we  are  not  able to obtain <font color="blue">adequate supplies</font> of our product     <font color="blue">candidates</font>,  it  will  be more <font color="blue">difficult</font> for us to develop our product     <font color="blue">candidates</font> and <font color="blue">compete <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> and any products     that we may develop <font color="blue">may compete with</font> other <font color="blue">product <font color="blue">candidates</font></font> and products     for  access  to  <font color="blue">manufacturing</font>  <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>For  example,  the active     <font color="blue">pharmaceutical</font> ingredient in <font color="blue">ACAPODENE </font>is also the <font color="blue">active <font color="blue">pharmaceutical</font></font>     ingredient in <font color="blue">FARESTON Orion </font>also <font color="blue">manufacture</font>s toremifene for <font color="blue">third parties</font>     for <font color="blue">sale outside</font> the <font color="blue"><font color="blue">United States</font> </font>for the treatment of <font color="blue">advanced breast</font>     cancer in post-menopausal women</td>
    </tr>
    <tr>
      <td>Our present or future <font color="blue">manufacturing</font> <font color="blue">partners may</font> not be able to comply     with FDA-mandated current <font color="blue">Good Manufacturing Practice </font><font color="blue">regulations</font>, other FDA     <font color="blue">regulatory</font> <font color="blue">requirements</font> or similar <font color="blue">regulatory</font> <font color="blue">requirements</font> outside the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Failure of our third-party <font color="blue">manufacture</font>rs or us to comply with     applicable  <font color="blue">regulations</font> could result in sanctions being imposed on us,     including  fines,  <font color="blue">injunctions</font>, civil penalties, failure of <font color="blue">regulatory</font>     <font color="blue">authorities</font> to grant <font color="blue">marketing approval</font> of our <font color="blue">product <font color="blue">candidates</font></font>, delays,     suspension or withdrawal of approvals, license revocation, seizures or     recalls  of <font color="blue">product <font color="blue">candidates</font></font> or products, operating <font color="blue">restrictions</font> and     criminal <font color="blue">prosecutions</font>, any of which could <font color="blue">significant</font>ly and <font color="blue"><font color="blue">adversely</font> affect</font>     supplies of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> on whom we rely do not perform <font color="blue">as contractually</font> required or     expected,  we  may  not  be  able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for or     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not have the ability to in<font color="blue">dependent</font>ly conduct <font color="blue"><font color="blue">clinical trial</font>s</font> for     our <font color="blue">product <font color="blue">candidates</font></font>, and we must rely on <font color="blue">third parties</font>, such as contract     research organizations, medical institutions, clinical investigators and     <font color="blue">contract laboratories</font> to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, we rely     on <font color="blue">third parties</font> to <font color="blue">assist with</font> our preclinical <font color="blue">development</font> of product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> do not <font color="blue">successfully</font> carry out their     <font color="blue">contractual duties</font> or <font color="blue">regulatory</font> <font color="blue">obligation</font>s or meet expected <font color="blue">deadlines</font>, if     the <font color="blue">third parties</font> need to be replaced, or if the quality or accuracy of the     data they obtain is <font color="blue">compromised due</font> to the failure to adhere to our clinical     protocols or <font color="blue">regulatory</font> <font color="blue">requirements</font> or for other reasons, our preclinical     <font color="blue">development</font>  <font color="blue">activities</font>  or  <font color="blue"><font color="blue">clinical trial</font>s</font> may be extended, delayed,     suspended  or  terminated, and we may not be able to obtain <font color="blue">regulatory</font>     approval for or <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [88]Table of <font color="blue">Contents       </font>We are <font color="blue">dependent</font> on our <font color="blue">collaborative</font> <font color="blue">arrangement</font> with <font color="blue">Ortho Biotech </font>to     develop and <font color="blue">commercialize</font> andarine, and we may be <font color="blue">dependent</font> upon <font color="blue">additional</font>     <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> to complete the <font color="blue">development</font> and <font color="blue">commercialization</font>     of some of our other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>     may place the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> outside our control, may     require us to <font color="blue">relinquish</font> important rights or <font color="blue">may otherwise</font> be on terms     unfavorable to us</td>
    </tr>
    <tr>
      <td>Any loss of <font color="blue">Ortho Biotech </font>as a <font color="blue">collaborator</font> in the <font color="blue">development</font> or     <font color="blue">commercialization</font> of andarine, dispute over the terms of the <font color="blue">collaboration</font>     or other adverse <font color="blue">development</font> in our <font color="blue">relationship with</font> <font color="blue">Ortho Biotech </font>could     <font color="blue">materially harm</font> our business and <font color="blue">might accelerate</font> our need for <font color="blue">additional</font>     capital</td>
    </tr>
    <tr>
      <td>We may not be successful in entering into <font color="blue">additional</font> <font color="blue">collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font>  with  <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">enter into</font> <font color="blue">additional</font>     <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> on favorable terms, it <font color="blue">could delay</font> or impair our     ability  to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> and could     increase our costs of <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>, including our <font color="blue">arrangement</font>     with <font color="blue">Ortho Biotech </font>for the <font color="blue">development</font> of andarine, subjects us to a number     of risks, including:       •   we may not be able to control the amount and timing of resources that     our <font color="blue">partners may</font> devote to the <font color="blue">product <font color="blue">candidates</font></font>;         •   our <font color="blue">partners may</font> experience financial <font color="blue">difficult</font>ies;         •   we may be required to <font color="blue">relinquish</font> important rights such as marketing     and <font color="blue">distribution</font> rights;         •   should a <font color="blue">collaborator</font> fail to develop or <font color="blue">commercialize</font> one of our     compounds or <font color="blue">product <font color="blue">candidates</font></font>, we may not receive any <font color="blue">future milestone</font>     payments and will not receive any royalties for this compound or product     candidate;         •   business <font color="blue"><font color="blue">combination</font>s</font> or <font color="blue">significant</font> changes in a <font color="blue">collaborator</font>’s     business strategy may also <font color="blue"><font color="blue">adversely</font> affect</font> a <font color="blue">collaborator</font>’s willingness or     ability to complete its <font color="blue">obligation</font>s under any <font color="blue">arrangement</font>;         •   a <font color="blue">collaborator</font> could move <font color="blue">forward with</font> a <font color="blue">competing <font color="blue">product candidate</font></font>     developed either in<font color="blue">dependent</font>ly or in <font color="blue">collaboration</font> with others, including     our <font color="blue">competitors</font>; and         •   the <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> are <font color="blue">often terminated</font> or allowed to     expire, <font color="blue">which would delay</font> the <font color="blue">development</font> and may increase the cost of     developing our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Intellectual Property       Our <font color="blue">license <font color="blue">agreement</font> with</font> Orion excludes the use of toremifene in humans to     <font color="blue">treat <font color="blue"><font color="blue">breast cancer</font> outside</font></font> the <font color="blue"><font color="blue">United States</font> </font>and may limit our ability to     market <font color="blue">ACAPODENE </font>for human uses of toremifene outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">exclusive license from</font> Orion excludes the use of toremifene for the     treatment of <font color="blue"><font color="blue">breast cancer</font> outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Orion has licensed to     other parties the right to market, sell and distribute toremifene for the     treatment of <font color="blue">advanced breast</font> cancer outside the <font color="blue"><font color="blue">United States</font> </font>and could     license <font color="blue">additional</font> parties to market, sell and distribute toremifene for     this <font color="blue">indication</font> outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Under the terms of our <font color="blue">license <font color="blue">agreement</font> with</font> Orion, Orion may require     us to modify our final <font color="blue">ACAPODENE </font><font color="blue">development</font> plans for <font color="blue">specified major</font>     <font color="blue">markets outside</font> the <font color="blue"><font color="blue">United States</font> </font>if those <font color="blue">development</font> plans <font color="blue">could <font color="blue">adversely</font></font>     affect Orion’s or Orion’s other licensees’ <font color="blue">activities</font> related <font color="blue">to <font color="blue">FARESTON     </font></font>for <font color="blue"><font color="blue">breast cancer</font> outside</font> the <font color="blue"><font color="blue">United States</font> </font>or toremifene-based animal     health products</td>
    </tr>
    <tr>
      <td>Although we do not believe that our <font color="blue">development</font> plans     <font color="blue"><font color="blue">adversely</font> affect</font> these <font color="blue">activities</font>, any future modifications to our plans     <font color="blue">imposed by</font> Orion may limit our ability to maximize the <font color="blue">commercial potential</font>     of <font color="blue">ACAPODENE </font>         Furthermore, we and our <font color="blue">affiliates</font> are <font color="blue">prohibited from marketing</font> or     <font color="blue">selling products containing toremifene</font> or related SERM compounds for human     use (1) in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">major countries</font> located outside the     <font color="blue">European Union </font>during the term of Orion’s <font color="blue"><font color="blue">patents covering</font> toremifene</font> in     <font color="blue">such countries</font> and (2) in <font color="blue">major countries</font> in the <font color="blue">European Union </font>through     October 2006, other than in the <font color="blue">dosage forms</font> or <font color="blue"><font color="blue">formulation</font>s which</font> are, or     may in the future be, <font color="blue">manufacture</font>d by Orion under our <font color="blue">agreement</font> with Orion</td>
    </tr>
    <tr>
      <td>The binding effect of this <font color="blue">non<font color="blue">competition</font> provision on us</font> and our <font color="blue">affiliates</font>     may make it more <font color="blue">difficult</font> for us to be acquired by some <font color="blue">potential buyers</font>     during                                         32       _________________________________________________________________    [89]Table of <font color="blue">Contents       </font>the relevant time periods even if we determine that a sale of the company     would be in the <font color="blue">best interests</font> of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If some or all of our, or our <font color="blue">licensors</font>’, patents expire or are invalidated     or  are  found  to  be  unenforceable, or if some or all of our patent     <font color="blue"><font color="blue">application</font>s</font>  do not <font color="blue">yield <font color="blue">issued patents</font></font> or <font color="blue">yield <font color="blue">patents with</font></font> narrow     claims, or if we are <font color="blue">estopped from</font> asserting that the claims of an issued     <font color="blue">patent cover</font> a product of a <font color="blue">third party</font>, we may be subject to <font color="blue">competition</font>     from  third  <font color="blue">parties with products with</font> the same <font color="blue">active <font color="blue">pharmaceutical</font></font>     <font color="blue">ingredients as</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">commercial success</font> will depend</font> in part on obtaining and maintaining     patent and <font color="blue">trade secret protection</font> for our <font color="blue">product <font color="blue">candidates</font></font>, the methods     for  treating  patients in the product <font color="blue">indication</font>s using these product     <font color="blue">candidates</font> and the <font color="blue">methods used</font> to synthesize these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We     will be able to protect our <font color="blue">product <font color="blue">candidates</font></font> and the methods for treating     patients in the product <font color="blue">indication</font>s using these <font color="blue">product <font color="blue">candidates</font></font> from     <font color="blue">unauthorized</font>  use  by  <font color="blue">third parties</font> only to the extent that we or our     <font color="blue">exclusive <font color="blue">licensors</font></font> own or <font color="blue">control such valid</font> and <font color="blue">enforceable patents</font> or     <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our rights to specified patent <font color="blue"><font color="blue">application</font>s</font> relating to SARM     compounds that we have <font color="blue">licensed from</font> UTRF, are subject to the terms of     UTRF’s <font color="blue">license with</font> The Ohio State University, or OSU, and our rights to     future related <font color="blue">improvements</font> are subject to UTRF’s exercise of an exclusive     <font color="blue">option under</font> its <font color="blue">agreement</font> with OSU for such <font color="blue">improvements</font>, which UTRF can     exercise at no <font color="blue">additional</font> cost to it</td>
    </tr>
    <tr>
      <td>In addition, under the terms of our     <font color="blue"><font color="blue">agreement</font>s</font>  with the <font color="blue">diagnostic companies</font> to which we <font color="blue">provide clinical</font>     <font color="blue">samples from</font> our <font color="blue">Phase IIb </font><font color="blue">clinical trial</font> of ACAPODENE, we will not obtain     any <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> in any of their <font color="blue">development</font>s, including any     test developed to detect high grade PIN or <font color="blue">prostate cancer</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">product <font color="blue">candidates</font></font> and the methods for <font color="blue">treating patients</font> in     the product <font color="blue">indication</font>s using these <font color="blue">product <font color="blue">candidates</font></font> are <font color="blue">covered by valid</font>     and <font color="blue">enforceable patents</font> and have claims <font color="blue">with sufficient scope</font> and support in     the <font color="blue">specification</font>, the <font color="blue">patents will provide protection only</font> for a limited     amount of time</td>
    </tr>
    <tr>
      <td>For example, the patent that we have <font color="blue">licensed from</font> <font color="blue">Orion     </font>covering the <font color="blue">composition</font> of matter of <font color="blue">toremifene expires</font> in the United     States in 2009</td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">counterparts</font> of this patent have <font color="blue">either already</font>     expired or will expire in Australia, Italy, Sweden and Switzerland in 2008,     that is, before we <font color="blue">commercialize</font> <font color="blue">ACAPODENE </font>As a result, outside the United     States and in the <font color="blue"><font color="blue">United States</font> </font>after 2009, we will need to <font color="blue">rely primarily</font>     on the <font color="blue">protection afforded by method</font> of use patents, relating to the use of     <font color="blue">ACAPODENE </font>for the relevant product <font color="blue">indication</font>s that have <font color="blue">been issued</font> or may     be <font color="blue">issued from</font> our owned or licensed patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>To date, most of     our <font color="blue"><font color="blue">application</font>s</font> for method of <font color="blue">use patents filed</font> for <font color="blue">ACAPODENE </font>outside of     the <font color="blue"><font color="blue">United States</font> </font>are <font color="blue">still pending</font> and have not <font color="blue">yielded <font color="blue">issued patents</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  intend  to  apply, if <font color="blue">appropriate</font>, for <font color="blue">regulatory</font> market     <font color="blue">exclusivity</font> and extensions of <font color="blue">patent term</font> under applicable European and     <font color="blue"><font color="blue">United States</font> </font>laws, we might not be able to secure any such <font color="blue">regulatory</font>     <font color="blue">exclusivity</font> or extension of <font color="blue">patent term</font></td>
    </tr>
    <tr>
      <td>We are not eligible for any such     <font color="blue">exclusivity</font> or <font color="blue">further extension</font> of the <font color="blue">composition</font> of matter patent of     toremifene in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our  and  our  <font color="blue">licensors</font>’ ability to obtain patents can be highly     uncertain and involve complex and in some <font color="blue">cases unsettled legal issues</font> and     factual  questions</td>
    </tr>
    <tr>
      <td>Furthermore,  <font color="blue">different</font>  countries have <font color="blue">different</font>     procedures for obtaining patents, and <font color="blue">patents issued</font> in <font color="blue">different</font> countries     provide  <font color="blue">different</font> degrees of <font color="blue">protection against</font> the use of a patented     <font color="blue">invention by others</font></td>
    </tr>
    <tr>
      <td>Therefore, if the issuance to us or our <font color="blue">licensors</font>, in a     <font color="blue">given country</font>, of a <font color="blue">patent cover</font>ing an invention is not <font color="blue">followed by</font> the     issuance, in other countries, of <font color="blue">patents covering</font> the <font color="blue">same invention</font>, or if     any <font color="blue">judicial interpretation</font> of the validity, enforceability or scope of the     claims  in  a  patent  issued  in  one  country  is not similar to the     <font color="blue">interpretation given</font> to the <font color="blue">corresponding patent issued</font> in another country,     our ability to protect our <font color="blue"><font color="blue">intellectual</font> property</font> in those <font color="blue">countries may</font> be     limited</td>
    </tr>
    <tr>
      <td>Changes in either <font color="blue">patent laws</font> or in <font color="blue">interpretations</font> of <font color="blue">patent laws</font>     in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">countries may</font> diminish the value of our     <font color="blue"><font color="blue">intellectual</font> property</font> or narrow the scope of our <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>Even if patents are issued to us or our <font color="blue">licensors</font> regarding our product     <font color="blue">candidates</font> or methods of using them, those patents can be <font color="blue">challenged by</font> our     <font color="blue">competitors</font> who can <font color="blue">argue such patents</font> are invalid or unenforceable or that     the claims of the <font color="blue"><font color="blue">issued patents</font> should</font> be limited or <font color="blue">narrowly construed</font></td>
    </tr>
    <tr>
      <td>Patents also will not protect our <font color="blue">product <font color="blue">candidates</font></font> if <font color="blue">competitors</font> devise     ways of making or using these <font color="blue">product <font color="blue">candidates</font></font> without legally infringing     our patents</td>
    </tr>
    <tr>
      <td>The Federal Food, Drug, and Cosmetic Act and FDA <font color="blue">regulations</font>     and policies create a <font color="blue">regulatory</font> environment that <font color="blue">encourages companies</font> to     <font color="blue">challenge branded drug patents</font> or to create <font color="blue">noninfringing versions</font> of a     <font color="blue">patented product</font> in order to <font color="blue">facilitate</font> the approval of <font color="blue">abbreviated new drug</font>     <font color="blue"><font color="blue">application</font>s</font>  for  <font color="blue">generic substitutes</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">same types</font> of <font color="blue">incentives</font>     encourage  <font color="blue">competitors</font>  to  submit  new drug <font color="blue"><font color="blue">application</font>s</font> that rely on     literature  and <font color="blue">clinical data</font> not prepared for or by the <font color="blue">drug sponsor</font>,     providing another <font color="blue">less burdensome pathway</font> to approval</td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________    [90]Table of <font color="blue"><font color="blue">Contents       </font>     </font>We also rely on <font color="blue">trade secrets</font> to protect our technology, especially     where we do not believe that <font color="blue">patent protection</font> is <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>Our employees, consultants,     <font color="blue">contractors</font>,  outside  scientific <font color="blue">collaborator</font>s and other <font color="blue">advisors may</font>     <font color="blue">unintentionally</font>  or willfully disclose our <font color="blue">confidential</font> information to     <font color="blue">competitors</font>, and <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> may not provide an adequate     remedy in the event of <font color="blue">unauthorized</font> disclosure of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">Enforcing </font>a claim that a <font color="blue">third party</font> illegally obtained and is using our     trade  secrets  is  expensive  and  time-consuming, and the outcome is     unpredictable</td>
    </tr>
    <tr>
      <td>Moreover,  our  <font color="blue">competitors</font>  may in<font color="blue">dependent</font>ly develop     equivalent knowledge, methods and know-how</td>
    </tr>
    <tr>
      <td>Failure to obtain or maintain     <font color="blue">trade secret protection</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">competitive</font> business     position</td>
    </tr>
    <tr>
      <td>Off-label sale or use of <font color="blue">toremifene products</font> <font color="blue">could decrease</font> our sales of     <font color="blue">ACAPODENE </font> and  could lead to <font color="blue">pricing pressure</font> if <font color="blue">such product</font>s become     available at <font color="blue">competitive</font> prices and in dosages that are <font color="blue">appropriate</font> for the     <font color="blue">indication</font>s for which we are developing <font color="blue">ACAPODENE </font>         In all countries in which we hold or have licensed rights to patents or     patent <font color="blue"><font color="blue">application</font>s</font> related to ACAPODENE, the <font color="blue">composition</font> of matter patents     we license from Orion will expire before our method of use patents, and in     some <font color="blue">countries outside</font> the <font color="blue">United States</font>, the <font color="blue">composition</font> of matter patents     have already expired</td>
    </tr>
    <tr>
      <td>Our method of use patents may not protect <font color="blue">ACAPODENE </font>    from the risk of off-label sale or use of other <font color="blue">toremifene products</font> in place     of <font color="blue">ACAPODENE </font>Physicians are permitted to <font color="blue">prescribe legally available drugs</font>     for uses that are not described in the drug’s labeling and that <font color="blue">differ from</font>     those uses tested and <font color="blue">approved by</font> the FDA or its equivalent</td>
    </tr>
    <tr>
      <td>Such off-label     uses are <font color="blue">common across medical specialties</font> and are <font color="blue"><font color="blue">particularly</font> prevalent</font>     for <font color="blue">cancer treatments</font></td>
    </tr>
    <tr>
      <td>Any off-label sales of toremifene may <font color="blue">adversely</font>     affect  our ability to <font color="blue"><font color="blue">generate revenue</font> from</font> the sale of ACAPODENE, if     approved for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Even in the event that patents are <font color="blue">issued from</font> our <font color="blue">pending method</font> of     use patent <font color="blue"><font color="blue">application</font>s</font>, after the expiration of the <font color="blue">patent cover</font>ing the     <font color="blue">composition</font> of matter of toremifene in a <font color="blue">particular country</font>, <font color="blue">competitors</font>     <font color="blue">could market</font> and <font color="blue">sell <font color="blue">toremifene products</font></font> for uses for which FARESTON has     <font color="blue">already <font color="blue">been approved</font></font></td>
    </tr>
    <tr>
      <td>Thus, physicians in <font color="blue">such countries</font> would be permitted     to  prescribe these other <font color="blue">toremifene products</font> for <font color="blue">indication</font>s that are     <font color="blue">protected by</font> our method of use patents or <font color="blue">patents issuing from pending</font>     patent <font color="blue"><font color="blue">application</font>s</font>, even though these <font color="blue">toremifene products</font> would not have     <font color="blue">been approved</font> for those uses, and in most cases the <font color="blue">competitor would</font> not be     liable for infringing our patents</td>
    </tr>
    <tr>
      <td>Moreover, because Orion has licensed and     could  further  license  other  parties to market, sell and distribute     toremifene for <font color="blue"><font color="blue">breast cancer</font> outside</font> the <font color="blue">United States</font>, physicians in such     <font color="blue">countries could prescribe</font> these <font color="blue">products sold pursuant</font> to another <font color="blue">Orion     </font>license off-label</td>
    </tr>
    <tr>
      <td>This <font color="blue">further increases</font> the risk of off-label <font color="blue">competition</font>     developing for <font color="blue">ACAPODENE </font>for the <font color="blue">indication</font>s for which we are developing     this <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>In addition, if no patents are <font color="blue">issued with respect</font>     to our <font color="blue">pending method</font> of use patent <font color="blue"><font color="blue">application</font>s</font> related to the use of     ACAPODENE, after the expiration of the <font color="blue">patent cover</font>ing the <font color="blue">composition</font> of     matter of toremifene in a <font color="blue">particular country</font>, we would have no patent to     prevent  <font color="blue">competitors</font>  from  marketing  and <font color="blue">selling generic versions</font> of     <font color="blue">toremifene at doses</font> and in <font color="blue">formulation</font>s equivalent to <font color="blue">ACAPODENE </font>for the     <font color="blue">indication</font>s covered by our <font color="blue">pending method</font> of use patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>If  we  infringe <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of <font color="blue">third parties</font>, it may     increase  our costs or <font color="blue">prevent us from</font> being able to <font color="blue">commercialize</font> our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>There is a risk that we are infringing the <font color="blue">proprietary rights</font> of third     parties  because numerous <font color="blue"><font color="blue">United States</font> </font>and foreign <font color="blue">issued patents</font> and     pending patent <font color="blue"><font color="blue">application</font>s</font>, which are owned by <font color="blue">third parties</font>, exist in the     fields that are the focus of our <font color="blue">drug discovery</font> and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Others might have been the first to make the <font color="blue">inventions</font> covered by each of     our or our <font color="blue">licensors</font>’ pending patent <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">issued patents</font> and     might have been the first to file patent <font color="blue"><font color="blue">application</font>s</font> for these <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In addition, because patent <font color="blue"><font color="blue">application</font>s</font> can take many years to issue, there     may be currently pending <font color="blue"><font color="blue">application</font>s</font>, unknown to us or our <font color="blue">licensors</font>, which     may later result in <font color="blue">issued patents</font> that cover the production, <font color="blue">manufacture</font>,     <font color="blue">commercialization</font>,  <font color="blue">formulation</font>  or  use of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In     addition, the production, <font color="blue">manufacture</font>, <font color="blue">commercialization</font>, <font color="blue">formulation</font> or use     of our <font color="blue">product <font color="blue">candidates</font></font> may infringe existing patents of which we are not     aware</td>
    </tr>
    <tr>
      <td><font color="blue">Defending </font>ourselves against third-party claims, including <font color="blue">litigation</font>     in  particular,  would  be  costly and time consuming and <font color="blue">would divert</font>     <font color="blue">management</font>’s attention from our business, <font color="blue">which could lead</font> to delays in our     <font color="blue">development</font> or <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> are successful in     their claims, we might have to pay substantial damages or take other actions     that are adverse to our business</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> claims, or to avoid     potential claims, we might:       •   be <font color="blue">prohibited from selling</font> or licensing any product that we may     develop unless the <font color="blue">patent holder</font> licenses the patent to us, which the patent     holder is not required to do;                                         34       _________________________________________________________________    [91]Table of <font color="blue">Contents       </font>  •   be required to pay substantial royalties or grant a <font color="blue">cross license</font> to     our patents to another <font color="blue">patent holder</font>; or         •   be required to redesign the <font color="blue">formulation</font> of a <font color="blue">product candidate</font> so it     does not infringe, which may not be possible or could require substantial     funds and time</td>
    </tr>
    <tr>
      <td>Risk Related to Regulatory Approval of Our Product Candidates       If we are not able to obtain required <font color="blue"><font color="blue">regulatory</font> approval</font>s, we will not be     able to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, and our ability to generate     <font color="blue">revenue will</font> be <font color="blue">materially impaired</font></td>
    </tr>
    <tr>
      <td>Our  product  <font color="blue">candidates</font> and the <font color="blue">activities</font> associated with their     <font color="blue">development</font> and <font color="blue">commercialization</font> are subject to <font color="blue">comprehensive regulation by</font>     the  FDA,  and  other  <font color="blue">regulatory</font> agencies in the <font color="blue"><font color="blue">United States</font> </font>and by     comparable <font color="blue">authorities</font> in other countries</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue">regulatory</font>     approval for a <font color="blue">product candidate</font> will <font color="blue">prevent us from</font> <font color="blue">commercializing</font> the     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We have not received <font color="blue"><font color="blue">regulatory</font> approval</font> to market any of     our <font color="blue">product <font color="blue">candidates</font></font> in any <font color="blue">jurisdiction</font> and have only limited experience     in  preparing and filing the <font color="blue"><font color="blue">application</font>s</font> <font color="blue">necessary</font> to gain <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s is expensive, often     takes many years, if approval is obtained at all, and can <font color="blue">vary substantially</font>     based  upon the type, <font color="blue">complexity</font> and novelty of the <font color="blue">product <font color="blue">candidates</font></font>     involved</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in the <font color="blue"><font color="blue">regulatory</font> approval</font> policy during the <font color="blue">development</font>     period, changes in or the <font color="blue">enactment</font> of <font color="blue">additional</font> <font color="blue">regulations</font> or statutes,     or changes in <font color="blue">regulatory</font> review for each submitted product <font color="blue">application</font>, may     cause delays in the approval or rejection of an <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Even if the FDA     approves  a  product  candidate,  the  approval may impose <font color="blue">significant</font>     <font color="blue">restrictions</font>  on  the  indicated  uses,  <font color="blue">conditions</font> for use, labeling,     <font color="blue">advertising</font>, promotion, marketing and/or production of <font color="blue">such product</font>, and may     impose ongoing <font color="blue">requirements</font> for post-approval studies, including <font color="blue">additional</font>     research  and <font color="blue">development</font> and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">also may impose</font>     <font color="blue">various civil</font> or <font color="blue">criminal sanctions</font> for failure to comply with <font color="blue">regulatory</font>     <font color="blue">requirements</font>, including withdrawal of <font color="blue">product approval</font></td>
    </tr>
    <tr>
      <td>Furthermore, the approval procedure and the time required to obtain     <font color="blue">approval varies among countries</font> and can involve <font color="blue">additional</font> testing beyond     that required by the FDA Approval by one <font color="blue">regulatory</font> authority does not     ensure approval by <font color="blue">regulatory</font> <font color="blue">authorities</font> in other <font color="blue">jurisdiction</font>s</td>
    </tr>
    <tr>
      <td>The FDA has substantial <font color="blue">discretion</font> in the approval process and may     refuse  to  accept  any  <font color="blue">application</font>  or  may decide that our data are     insufficient for approval and require <font color="blue">additional</font> preclinical, clinical or     other studies</td>
    </tr>
    <tr>
      <td>For example, we believe that if the results of our ongoing     <font color="blue">Phase III </font><font color="blue">clinical trial</font> of <font color="blue">ACAPODENE </font>for the reduction in the incidence of     <font color="blue">prostate cancer</font> in <font color="blue">men with high grade</font> PIN are sufficiently positive, that     trial will be sufficient to serve as a <font color="blue">single pivotal</font> <font color="blue">Phase III </font>clinical     trial for this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2005, we received a Special Protocol     Assessment from the <font color="blue">FDA A SPA </font>is designed to <font color="blue">facilitate</font> the FDA’s review     and  approval  of <font color="blue">drug products by allowing</font> the agency to evaluate the     <font color="blue">proposed design</font> and size of <font color="blue"><font color="blue">clinical trial</font>s</font> that are intended to form the     <font color="blue">primary basis</font> for determining a drug product’s efficacy</td>
    </tr>
    <tr>
      <td>If <font color="blue">agreement</font> is     <font color="blue">reached with</font> the FDA, a SPA <font color="blue">documents</font> the terms and <font color="blue">conditions</font> under which     the design of the subject trial will be adequate for submission of the     efficacy and <font color="blue">human safety</font> portion of a NDA However, there are <font color="blue">circumstances</font>     under which we may not receive the benefits of the SPA, notably including if     the FDA <font color="blue">subsequently</font> identifies a substantial <font color="blue">scientific issue essential</font> to     determining  the  product’s  safety  or efficacy</td>
    </tr>
    <tr>
      <td>In addition, varying     <font color="blue">interpretations</font> of the data obtained <font color="blue">from preclinical</font> and <font color="blue">clinical testing</font>     <font color="blue">could delay</font>, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font> of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Furthermore, even if we file an <font color="blue">application</font> with the FDA for marketing     approval of a <font color="blue">product candidate</font>, it may not result in <font color="blue">marketing approval</font>     from the FDA          We do not expect to receive <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">commercial sale</font>     of any of our <font color="blue">product <font color="blue">candidates</font></font> that are in <font color="blue">development</font> for the next few     years</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to obtain FDA approval or <font color="blue">approval from comparable</font>     <font color="blue">authorities</font> in other countries for such <font color="blue">candidates</font> would <font color="blue">prevent us from</font>     <font color="blue">commercializing</font>  our  <font color="blue">product <font color="blue">candidates</font></font> in the <font color="blue"><font color="blue">United States</font> </font>or other     countries</td>
    </tr>
    <tr>
      <td>See the section entitled “Business — Government Regulation” under     Item 1 above for <font color="blue">additional</font> information regarding <font color="blue">risks associated with</font>     approval, as well as risks related to post-approval <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>35       _________________________________________________________________    [92]Table of <font color="blue"><font color="blue">Contents       </font>     </font>             Risks Related to Commercialization       The <font color="blue">commercial success</font> of any products that we may develop <font color="blue">will depend upon</font>     the degree of market <font color="blue">acceptance</font> among physicians, patients, health care     payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Any products that we may develop may not <font color="blue">gain market <font color="blue">acceptance</font> among</font>     physicians, patients, health care payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>If these     products do not achieve an <font color="blue">adequate level</font> of <font color="blue">acceptance</font>, we may not generate     material <font color="blue">product revenue</font>s, and we may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>The degree of     market <font color="blue">acceptance</font> of our <font color="blue">product <font color="blue">candidates</font></font>, if approved for commercial     sale, will depend on a number of factors, including:       •   the prevalence and severity of any side effects;         •   <font color="blue">potential advantages over alternative treatments</font>;         •   the ability to offer our <font color="blue">product <font color="blue">candidates</font></font> for sale at <font color="blue">competitive</font>     prices;         •   <font color="blue">relative convenience</font> and ease of <font color="blue">administration</font>;         •   the strength of marketing and <font color="blue">distribution</font> support; and         •   sufficient third-party coverage or <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">only marketed product generating revenue</font> is FARESTON FARESTON is     subject to a number of risks that may cause sales of FARESTON to continue to     decline</td>
    </tr>
    <tr>
      <td>FARESTON is currently our <font color="blue">only marketed product generating sales</font></td>
    </tr>
    <tr>
      <td>Sales     of FARESTON in the <font color="blue"><font color="blue">United States</font> </font>have <font color="blue">been declining</font></td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font>sales of     FARESTON could be <font color="blue">impacted by</font> many factors</td>
    </tr>
    <tr>
      <td>The occurrence of one or more of     the <font color="blue">following risks may</font> cause sales of FARESTON to decline:       •   the loss of the <font color="blue">availability</font> of Orion’s website to market FARESTON,     which is an <font color="blue">important source</font> of <font color="blue">advertising</font>;          •     the  loss  of one or more of our <font color="blue">three largest wholesale drug</font>     distributors, which accounted for approximately 94prca of our <font color="blue">revenue generated</font>     from the sale of FARESTON for the year ended <font color="blue">December </font>31, 2005;         •   the <font color="blue">continued success</font> of <font color="blue">competing products</font>, including aromatase     <font color="blue">inhibitors</font>;         •   the loss of coverage or <font color="blue">reimbursement</font> for FARESTON from Medicare and     Medicaid, <font color="blue">private health insurers</font> or other third-party payors;         •   exposure to <font color="blue">product <font color="blue">liability</font></font> claims related to the <font color="blue">commercial sale</font> of     FARESTON, <font color="blue">which may exceed</font> our <font color="blue">product <font color="blue">liability</font></font> insurance;         •   the failure of Orion to maintain <font color="blue">regulatory</font> filings or comply with     applicable FDA <font color="blue">requirements</font> with respect to FARESTON;         •   the ability of <font color="blue">third parties</font> to market and sell generic toremifene     products that will compete with FARESTON for the treatment of <font color="blue">breast cancer</font>     after the <font color="blue">composition</font> of matter patents that we license from Orion expire in     the <font color="blue"><font color="blue">United States</font> </font>in 2009;         •   the loss of Orion, upon which we rely as a single source, as our     supplier of FARESTON; and         •   our <font color="blue">inability</font> to <font color="blue">manufacture</font> FARESTON until Orion’s <font color="blue">patents with</font>     respect  to  the  <font color="blue">composition</font>  of matter of toremifene expire if <font color="blue">Orion     </font>terminates our license and supply <font color="blue">agreement</font> due to our uncured material     breach or <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>If we are unable to expand our sales and marketing <font color="blue">capabilities</font> or enter     into  <font color="blue"><font color="blue">agreement</font>s</font>  with  third  parties  to market and sell our product     <font color="blue">candidates</font>,  we  may  be  unable to generate <font color="blue">product revenue</font> from such     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have limited experience as a company in the sales, marketing and     <font color="blue">distribution</font> of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>There are <font color="blue">risks involved with</font>     building our own sales and marketing <font color="blue">capabilities</font>, as well as entering into     <font color="blue"><font color="blue">arrangement</font>s</font> <font color="blue">with <font color="blue">third parties</font></font> to perform these services</td>
    </tr>
    <tr>
      <td>For example,     building a <font color="blue">sales force</font> is expensive and time-consuming and <font color="blue">could delay</font> any     launch of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>In addition, to the extent that we <font color="blue">enter into</font>     <font color="blue"><font color="blue">arrangement</font>s</font> <font color="blue">with <font color="blue">third parties</font></font> to perform sales, marketing and <font color="blue">distribution</font>     services, our <font color="blue">product revenue</font>s are likely to be lower than if we market and     sell any products that we develop ourselves</td>
    </tr>
    <tr>
      <td>36       _________________________________________________________________    [93]Table of <font color="blue">Contents       </font>If  we  are  unable to obtain <font color="blue">adequate coverage</font> and <font color="blue">reimbursement</font> from     third-party payors for products we sell at acceptable prices, our revenues     and prospects for <font color="blue"><font color="blue">profitability</font> will suffer</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">patients will</font> not be capable of paying for any products that we     may develop and <font color="blue">will rely on</font> Medicare and Medicaid, <font color="blue">private health insurers</font>     and other third-party payors to pay for their medical needs</td>
    </tr>
    <tr>
      <td>If third-party     payors do not <font color="blue">provide coverage</font> or <font color="blue">reimbursement</font> for any products that we may     develop,  our  revenues and prospects for <font color="blue"><font color="blue">profitability</font> may suffer</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">December </font>2003,  the President of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">signed into law</font> the     Medicare Prescription Drug, Improvement and Modernization Act of 2003,     <font color="blue">legislation</font>  creating a <font color="blue">prescription</font> drug benefit program <font color="blue">for Medicare     </font><font color="blue">recipients</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">prescription</font> drug program established by the <font color="blue">legislation</font> may     have  the effect of reducing the prices that we are able to charge for     products we develop and <font color="blue">sell through</font> the program</td>
    </tr>
    <tr>
      <td>This <font color="blue">prescription</font> drug     <font color="blue">legislation</font>  may  also cause third-party payors other than the federal     <font color="blue">government</font>, including the states under the Medicaid program, to <font color="blue">discontinue</font>     coverage for products that we may develop or to lower the amount that they     pay</td>
    </tr>
    <tr>
      <td><font color="blue">State Medicaid </font><font color="blue">programs generally</font> have outpatient <font color="blue">prescription</font> drug     coverage, subject to state <font color="blue">regulatory</font> <font color="blue">restrictions</font>, for the population     eligible for Medicaid</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of coverage or <font color="blue">reimbursement</font> for     <font color="blue">prescription</font> drugs under private health insurance and <font color="blue">managed care</font> plans     <font color="blue">varies based on</font> the type of contract or plan purchased</td>
    </tr>
    <tr>
      <td>A <font color="blue">primary trend</font> in the <font color="blue"><font color="blue">United States</font> </font><font color="blue">health care industry</font> is toward     <font color="blue">cost containment</font></td>
    </tr>
    <tr>
      <td>In addition, in some foreign countries, <font color="blue">particularly</font> the     countries of the European Union, the pricing of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s     is subject to <font color="blue">government</font>al control</td>
    </tr>
    <tr>
      <td>In these countries, pricing negotiations     with <font color="blue">government</font>al <font color="blue">authorities</font> can take six to 12 months or longer after the     receipt  of  <font color="blue">regulatory</font>  marketing  approval  for a product</td>
    </tr>
    <tr>
      <td>To obtain     <font color="blue">reimbursement</font> or <font color="blue">pricing approval</font> in some countries, we may be required to     conduct a <font color="blue">clinical trial</font> that compares the <font color="blue">cost <font color="blue">effective</font>ness</font> of our product     <font color="blue">candidates</font> or products to other <font color="blue">available therapies</font></td>
    </tr>
    <tr>
      <td>The conduct of such a     clinical  trial  could  be  expensive  and  result  in  delays  in our     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">challenging</font> the <font color="blue">prices charged</font> for     medical  products  and  services,  and  many  third-party payors limit     <font color="blue">reimbursement</font>  for newly-approved health care products</td>
    </tr>
    <tr>
      <td>In particular,     third-party payors may limit the <font color="blue">indication</font>s for which they <font color="blue">will reimburse</font>     patients who use any products that we may develop or products we sell</td>
    </tr>
    <tr>
      <td>Cost-control initiatives <font color="blue">could decrease</font> the price we <font color="blue">might establish</font> for     products that we may develop or that we sell, which would result in lower     <font color="blue">product revenue</font>s to us</td>
    </tr>
    <tr>
      <td>Another <font color="blue">development</font> that may affect the pricing of drugs is proposed     <font color="blue">Congressional </font>action regarding <font color="blue">drug <font color="blue">reimportation</font> into</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The Medicare Prescription Drug, Improvement and Modernization Act of 2003     gives <font color="blue">discretion</font> <font color="blue">to the Secretary of Health and Human Services </font>to allow drug     <font color="blue">reimportation</font> into the <font color="blue"><font color="blue">United States</font> </font>under some <font color="blue">circumstances</font> from foreign     countries, including countries where the drugs are sold at a lower price     than in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Proponents </font>of drug <font color="blue">reimportation</font> may attempt to     pass <font color="blue">legislation</font> which would directly allow <font color="blue">reimportation</font> under certain     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">legislation</font> or <font color="blue">regulations</font> were <font color="blue">passed allowing</font> the     <font color="blue">reimportation</font> of drugs, they <font color="blue">could decrease</font> the price we receive for any     products  that  we  may develop, <font color="blue">negatively affecting</font> our revenues and     prospects for <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If  product  <font color="blue">liability</font>  lawsuits are <font color="blue">brought against us</font>, we will incur     substantial <font color="blue">liabilities</font> and may be required to limit <font color="blue">commercialization</font> of     any products that we may develop</td>
    </tr>
    <tr>
      <td>We face an inherent risk of <font color="blue">product <font color="blue">liability</font></font> exposure related to the     testing of our <font color="blue">product <font color="blue">candidates</font></font> in human <font color="blue"><font color="blue">clinical trial</font>s</font> and will face an     <font color="blue">even greater risk</font> if we <font color="blue">commercially sell</font> any product that we may develop</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> defend ourselves against claims that our product     <font color="blue">candidates</font>  or  products  caused  injuries,  we will incur substantial     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of merit or eventual outcome, <font color="blue">liability</font> claims may     result in:       •   decreased demand for any <font color="blue">product <font color="blue">candidates</font></font> or products;         •   injury to our reputation;         •   withdrawal of <font color="blue">clinical trial</font> participants;         •   costs to defend the related <font color="blue">litigation</font>;         •   substantial <font color="blue">monetary awards</font> to <font color="blue">trial participants</font> or patients;         •   loss of revenue; and         •   the <font color="blue">inability</font> to <font color="blue">commercialize</font> any products for which we obtain or     hold approvals</td>
    </tr>
    <tr>
      <td>We have <font color="blue">product <font color="blue">liability</font></font> insurance that covers our <font color="blue"><font color="blue">clinical trial</font>s</font> and     <font color="blue">commercial products up</font> to a dlra20dtta0 million annual aggregate limit</td>
    </tr>
    <tr>
      <td><font color="blue">Insurance     </font>coverage is <font color="blue">increasingly expensive</font></td>
    </tr>
    <tr>
      <td>We may not be able to maintain insurance                                         37       _________________________________________________________________    [94]Table of <font color="blue">Contents       </font>coverage at a <font color="blue">reasonable cost</font> and we may not be able to obtain insurance     coverage that will be adequate to satisfy any <font color="blue">liability</font> that may arise</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> are better able to develop and <font color="blue">market products than</font> any     products that we may develop, our <font color="blue">commercial opportunity will</font> be reduced or     eliminated</td>
    </tr>
    <tr>
      <td>We face <font color="blue">competition</font> from established <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font>     companies, as well as from academic institutions, <font color="blue">government</font> agencies and     private and <font color="blue">public research institutions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial opportunities will</font>     be  reduced or eliminated if our <font color="blue">competitors</font> develop and <font color="blue">commercialize</font>     products that are safer, more <font color="blue">effective</font>, have fewer side effects or are less     <font color="blue">expensive than</font> any products that we may develop</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">significant</font>     delays  in  the  <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> could allow our     <font color="blue">competitors</font> to <font color="blue">bring products</font> to market before us and impair our ability to     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Various products are <font color="blue">currently marketed</font> or sold and used off-label for     some of the diseases and <font color="blue">conditions</font> that we are targeting, and a number of     companies are or may be developing <font color="blue">new treatments</font></td>
    </tr>
    <tr>
      <td>The occurrence of such     off-label uses could <font color="blue">significant</font>ly reduce our ability to market and sell any     products that we may develop</td>
    </tr>
    <tr>
      <td>For example, although there are no products     that  have  been <font color="blue">approved by</font> the FDA to treat multiple side effects of     advanced <font color="blue">prostate cancer</font> therapy, we are aware of a number of <font color="blue">drugs marketed</font>     by   Eli   Lilly,  Merck,  Sanofi-Aventis,  Procter  &amp;  Gamble,  Wyeth     Pharmaceuticals, Boehringer Ingelheim and Bristol Myers Squibb that are     prescribed off-label to <font color="blue">treat single</font> side effects of this therapy; that     <font color="blue">external beam radiation</font> is used to <font color="blue">treat breast pain</font> and <font color="blue">enlargement</font>; and     that Amgen Inc</td>
    </tr>
    <tr>
      <td>is developing a <font color="blue">product candidate</font> for the treatment of bone     loss in post-cancer patients</td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">while there</font> are no drugs that have     been <font color="blue">approved by</font> the FDA for the treatment of <font color="blue">muscle wasting weight loss</font>     from cancer, there are <font color="blue">drugs marketed</font> by Steris Laboratories and Savient     Pharmaceuticals that are being prescribed off-label for the treatment of     some types of <font color="blue">muscle wasting weight loss</font> from cancer</td>
    </tr>
    <tr>
      <td><font color="blue">Testosterone </font>and other     <font color="blue">anabolic agents</font> are used to <font color="blue">treat involuntary weight loss</font> in patients who     have  acute  muscle  wasting</td>
    </tr>
    <tr>
      <td>Also,  TAP  Pharmaceuticals  and Ligand     Pharmaceuticals have <font color="blue">entered into</font> a <font color="blue">collaboration</font> <font color="blue">agreement</font> to develop a     SARM and may be initiating <font color="blue">Phase II </font>studies in 2006</td>
    </tr>
    <tr>
      <td>In addition, there may     be <font color="blue">product <font color="blue">candidates</font></font> of which we are not aware at an <font color="blue">earlier stage</font> of     <font color="blue">development</font>  that  <font color="blue">may compete with</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If any are     <font color="blue">successfully</font> developed and approved, they could compete directly with our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>This could result in <font color="blue">reduced sales</font> and <font color="blue">pricing pressure</font>     on our <font color="blue">product <font color="blue">candidates</font></font>, if approved, which in turn would reduce our     ability to <font color="blue">generate revenue</font> and have a <font color="blue">negative impact on</font> our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater financial resources     and  expertise in research and <font color="blue">development</font>, <font color="blue">manufacturing</font>, preclinical     testing, conducting <font color="blue"><font color="blue">clinical trial</font>s</font>, obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s and     marketing approved products than we do</td>
    </tr>
    <tr>
      <td>Smaller or early-stage companies may     also prove to be <font color="blue">significant</font> <font color="blue">competitors</font>, <font color="blue">particularly</font> through <font color="blue">collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font> with large and established companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">third parties</font>     compete  with  us in recruiting and retaining <font color="blue">qualified scientific</font> and     <font color="blue">management</font>  personnel,  <font color="blue">establishing</font>  <font color="blue">clinical trial</font> sites and patient     <font color="blue">registration</font> for <font color="blue"><font color="blue">clinical trial</font>s</font>, as well as in acquiring <font color="blue">technologies</font> and     <font color="blue">technology licenses complementary</font> to our programs or <font color="blue">advantageous</font> to our     business</td>
    </tr>
    <tr>
      <td>Risks Related to Employees and Growth       If  we  fail  to attract and keep senior <font color="blue">management</font> and <font color="blue">key scientific</font>     personnel, we may be unable to <font color="blue">successfully</font> develop or <font color="blue">commercialize</font> our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our <font color="blue">continued ability</font> to attract, retain and     motivate highly qualified <font color="blue">management</font>, clinical and <font color="blue">scientific personnel</font> and     on our ability to develop and maintain important <font color="blue">relationships</font> with leading     academic institutions, clinicians and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>If we are not able to     attract  and  keep  senior  <font color="blue">management</font>  and  <font color="blue">key scientific</font> personnel,     <font color="blue">particularly</font> Dr</td>
    </tr>
    <tr>
      <td>Mitchell S Steiner, we may not be able to <font color="blue">successfully</font>     develop or <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>All of our employees are     at-will employees and can terminate their <font color="blue">employment</font> at any time</td>
    </tr>
    <tr>
      <td>We do not     carry “key person” <font color="blue">insurance covering</font> members of senior <font color="blue">management</font>, other     than dlra15dtta0 million of <font color="blue">insurance covering</font> Dr</td>
    </tr>
    <tr>
      <td>We will need to hire <font color="blue">additional</font> employees in order to continue our clinical     trials and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to manage     future  growth  could  harm  our  ability to <font color="blue">commercialize</font> our product     <font color="blue">candidates</font>, increase our costs and <font color="blue"><font color="blue">adversely</font> impact</font> our ability to compete     <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>In order to continue our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">commercialize</font> our product     <font color="blue">candidates</font>,  we  will  need  to  expand  the number of our managerial,     operational, financial and other employees</td>
    </tr>
    <tr>
      <td>We currently anticipate that we     will need                                         38       _________________________________________________________________    [95]Table of <font color="blue">Contents       </font>between 150 and 250 <font color="blue">additional</font> employees by the time that <font color="blue">ACAPODENE </font>or     ostarine  is  initially  <font color="blue">commercialize</font>d,  including  50  to  100 sales     <font color="blue">representatives</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">competition</font>  for  qualified  personnel  in  the     <font color="blue">biotechnology</font> field is intense</td>
    </tr>
    <tr>
      <td>Future growth will impose <font color="blue">significant</font> added responsibilities on members     of  <font color="blue">management</font>,  including the need to identify, recruit, maintain and     integrate <font color="blue">additional</font> employees</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future financial performance</font> and our     ability to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> and to <font color="blue">compete <font color="blue">effective</font>ly</font>     will  depend,  in  part,  on  our  ability to manage any <font color="blue">future growth</font>     <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       Market <font color="blue"><font color="blue">volatility</font> may</font> cause our stock price and the value of your <font color="blue">investment</font>     to decline</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of <font color="blue">biotechnology</font> companies in general     have been <font color="blue">highly volatile</font> and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font> in the     future</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, in addition to other <font color="blue">risk factors described</font>     in this section, may have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our     <font color="blue">common stock</font>:       •   adverse results or delays in our <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   the timing of <font color="blue">achievement</font> of our clinical, <font color="blue">regulatory</font> and other     milestones, such as the <font color="blue">commencement</font> of clinical <font color="blue">development</font>, the <font color="blue">completion</font>     of a <font color="blue">clinical trial</font> or the receipt of <font color="blue"><font color="blue">regulatory</font> approval</font>;         •   <font color="blue">announcement</font> of FDA approval or non-approval of our <font color="blue">product <font color="blue">candidates</font></font>     or delays in the FDA <font color="blue">review process</font>;         •   actions taken by <font color="blue">regulatory</font> agencies with respect to our product     <font color="blue">candidates</font> or products, our <font color="blue"><font color="blue">clinical trial</font>s</font> or our sales and marketing     <font color="blue">activities</font>;         •   the <font color="blue">commercial success</font> of any product <font color="blue">approved by</font> the FDA or its     foreign <font color="blue">counterparts</font>;          •     the terms and timing of any <font color="blue">collaborative</font>, licensing or other     <font color="blue"><font color="blue">arrangement</font>s</font> that we <font color="blue">may establish</font>;         •   <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue"><font color="blue">United States</font> </font>and foreign countries;         •   changes in the structure of <font color="blue">health care payment systems</font>;         •   any <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> lawsuit involving us;         •   <font color="blue">announcement</font>s of <font color="blue">technological innovations</font> or <font color="blue">new products by us</font> or     our <font color="blue">competitors</font>;         •   market <font color="blue">conditions</font> for the <font color="blue">biotechnology</font> or <font color="blue">pharmaceutical</font> industries     in general;         •   actual or anticipated <font color="blue">fluctuations</font> in our results of operation;          •   changes in financial estimates or <font color="blue">recommendations by securities</font>     analysts;         •   sales of large blocks of our <font color="blue">common stock</font>;         •   sales of our <font color="blue">common stock</font> by our executive officers, <font color="blue">directors</font> and     <font color="blue">significant</font> <font color="blue">stockholders</font>;         •   changes in <font color="blue">accounting principles</font>; and         •   the loss of any of our <font color="blue">key scientific</font> or <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock markets</font> in general, and the markets for <font color="blue">biotechnology</font> stocks     in particular, have experienced <font color="blue">significant</font> <font color="blue">volatility</font> that has often been     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These broad     market <font color="blue">fluctuations</font> may <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">trading price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>In the past, class action <font color="blue">litigation</font> has often been instituted     against companies whose securities have experienced periods of <font color="blue">volatility</font> in     market  price</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">litigation</font> <font color="blue">brought against us</font> could result in     substantial costs, which would hurt our <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> and divert <font color="blue">management</font>’s attention and resources, which could     result in delays of our <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>39       _________________________________________________________________    [96]Table of <font color="blue">Contents       </font>Our officers, <font color="blue">directors</font> and largest <font color="blue"><font color="blue">stockholders</font> will</font> maintain the ability     to control all <font color="blue">matters submitted</font> to <font color="blue">stockholders</font> for approval</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>31, 2006, our officers, <font color="blue">directors</font> and holders of 5prca or     more of our outstanding <font color="blue">common stock</font> <font color="blue">beneficial</font>ly owned approximately 67dtta2prca     of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">stockholders</font>, acting     together, will be able to control all matters requiring approval by our     <font color="blue">stockholders</font>,  including the election of <font color="blue">directors</font> and the approval of     mergers or other business <font color="blue">combination</font> <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>The interests of this     group of <font color="blue">stockholders</font> may not <font color="blue">always coincide with</font> our interests or the     interests of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our charter <font color="blue">documents</font> and under <font color="blue">Delaware </font>law     could  make  an  <font color="blue">acquisition</font>  of  us,  which  may be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font>, more <font color="blue">difficult</font> and <font color="blue">may prevent <font color="blue">attempts by</font></font> our <font color="blue">stockholders</font> to     replace or remove our current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and our bylaws may delay     or prevent an <font color="blue">acquisition</font> of us or a change in our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In addition,     these <font color="blue">provisions may frustrate</font> or prevent any <font color="blue">attempts by</font> our <font color="blue">stockholders</font>     to replace or remove our current <font color="blue">management</font> by making it more <font color="blue">difficult</font> for     <font color="blue">stockholders</font> to <font color="blue">replace members</font> of our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Because our Board     of Directors is responsible for appointing the members of our <font color="blue">management</font>     team, these <font color="blue">provisions could</font> in turn affect any <font color="blue">attempt by</font> our <font color="blue">stockholders</font>     to <font color="blue">replace current members</font> of our <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>These provisions include:       •   a classified <font color="blue">Board of Directors</font>;         •   a <font color="blue">prohibition</font> on actions by our <font color="blue">stockholders</font> by written consent;         •   the ability of our <font color="blue">Board of Directors</font> to issue <font color="blue">preferred stock</font> without     stockholder approval, which could be used to institute a “poison pill” that     would work to dilute the stock ownership of a <font color="blue">potential hostile acquirer</font>,     <font color="blue">effective</font>ly preventing <font color="blue">acquisition</font>s that have not been <font color="blue">approved by</font> our Board     of Directors; and         •   <font color="blue">limitations</font> on the removal of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Moreover, because we are incorporated in Delaware, we are <font color="blue">governed by</font>     the provisions of Section 203 of the <font color="blue">Delaware </font>General Corporation Law, which     prohibits a person who owns in excess of 15prca of our <font color="blue">outstanding voting stock</font>     <font color="blue">from merging</font> or <font color="blue">combining with us</font> for a period of <font color="blue">three years</font> after the date     of the <font color="blue">transaction</font> in which the person acquired in excess of 15prca of our     <font color="blue">outstanding voting stock</font>, unless the merger or <font color="blue">combination</font> is approved in a     prescribed  manner</td>
    </tr>
    <tr>
      <td>Finally, these <font color="blue">provisions establish advance</font> notice     <font color="blue">requirements</font> for <font color="blue">nominations</font> for election to our <font color="blue">Board of Directors</font> or for     <font color="blue">proposing matters</font> that can be acted <font color="blue">upon at stockholder meetings</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">provisions would apply even</font> if the <font color="blue">offer may</font> be considered <font color="blue">beneficial</font> by     some <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our <font color="blue">total outstanding shares</font> are <font color="blue">restricted from</font>     <font color="blue">immediate resale but may</font> be sold into the market in the near future</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to drop <font color="blue">significant</font>ly, even     if our business is doing well</td>
    </tr>
    <tr>
      <td>For the 12-month period ended <font color="blue">December </font>31, 2005, the <font color="blue">average daily</font>     <font color="blue">trading volume</font> of our <font color="blue">common stock</font> on the <font color="blue">NASDAQ National Market </font>was less     than 55cmam937 shares</td>
    </tr>
    <tr>
      <td>As a result, future sales of a substantial number of     shares of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that such     sales may occur, could <font color="blue"><font color="blue">adversely</font> affect</font> the then-prevailing <font color="blue">market price</font> of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had 30cmam993cmam967 shares of     <font color="blue">common stock</font> outstanding</td>
    </tr>
    <tr>
      <td>Based on information <font color="blue">currently available</font> to us, all of the shares of     our <font color="blue">common stock</font> currently outstanding are eligible for sale in the public     market, subject in some cases to volume and other <font color="blue">limitations</font> under federal     <font color="blue">securities laws</font></td>
    </tr>
    <tr>
      <td>Moreover, JR Hyde, III, Oracle Partners, LP and Memphis Biomed     Ventures I, LP, three of our largest <font color="blue">stockholders</font>, and their <font color="blue">affiliates</font>,     have rights, subject to some <font color="blue">conditions</font>, to require us to file <font color="blue">registration</font>     <font color="blue">statements covering</font> the approximately 11dtta1 million shares of <font color="blue">common stock</font>     they hold in the <font color="blue">aggregate which</font> are subject to <font color="blue">registration</font> rights or to     include  these  shares in <font color="blue">registration</font> statements that we may file for     ourselves or other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Additionally, all shares of <font color="blue">common stock</font>     that we <font color="blue">may issue under</font> our <font color="blue">employee benefit</font> plans can be <font color="blue">freely sold</font> in the     <font color="blue">public market</font> upon issuance</td>
    </tr>
  </tbody>
</table>